Tokyo Tape
Sign in
← PeptiDream

Half-year report · Q2

4587.TEDINET S100U7ET
Period2024-01-01 → 2024-06-30
Filed2024-08-09
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥36.1bn2024-01-01 → 2024-06-30Cons.Revenue IFRS
Revenue¥28.7bn2023-01-01 → 2023-12-31Cons.Revenue IFRS (5-year summary)
Revenue¥9.4bn2023-01-01 → 2023-06-30Cons.Revenue IFRS
Operating income¥24.6bn2024-01-01 → 2024-06-30Cons.Operating profit loss IFRS
Operating income−¥986m2023-01-01 → 2023-06-30Cons.Operating profit loss IFRS
Profit before tax¥24.7bn2024-01-01 → 2024-06-30Cons.Profit loss before tax IFRS
Profit before tax¥4.4bn2023-01-01 → 2023-12-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥1.1bn2023-01-01 → 2023-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥729m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥17.9bn2024-01-01 → 2024-06-30Cons.Profit loss IFRS
Net income¥3.0bn2023-01-01 → 2023-12-31Cons.Profit loss IFRS (5-year summary)
Net income−¥729m2023-01-01 → 2023-06-30Cons.Profit loss IFRS
Total assets¥95.9bnat 2024-06-30Cons.Assets IFRS
Total assets¥69.5bnat 2023-12-31Cons.Assets IFRS
Total assets¥57.7bnat 2023-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥37.1bnat 2024-06-30Cons.Liabilities IFRS
Total liabilities¥29.1bnat 2023-12-31Cons.Liabilities IFRS
Net assets / equity¥58.8bnat 2024-06-30Cons.Equity IFRS
Net assets / equity¥40.3bnat 2023-12-31Cons.Equity IFRS
Net assets / equity¥31.0bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥32.0bnat 2022-12-31dCons.Equity IFRS
Equity (owners)¥58.8bnat 2024-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥40.3bnat 2023-12-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.0bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥25.5bnat 2024-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥19.5bnat 2023-12-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥11.2bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥5.2bnat 2022-12-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥2.7bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥12.4bn2023-01-01 → 2023-12-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥8.8bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥10.0bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow¥1.3bn2023-01-01 → 2023-12-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥798m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥1.5bn2024-01-01 → 2024-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥264m2023-01-01 → 2023-12-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥2.3bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥138.32024-01-01 → 2024-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.412023-01-01 → 2023-12-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-5.622023-01-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥138.112024-01-01 → 2024-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.382023-01-01 → 2023-12-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-5.622023-01-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio61.3%at 2024-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio58.1%at 2023-12-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio53.8%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-01-01 → 2024-06-30−¥178m
Reconciling Itemsreconcilingrevenue intersegment2024-01-01 → 2024-06-30−¥178m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥28.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2024-01-01 → 2024-06-30¥24.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-06-30¥7.8bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-06-30¥7.7bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2024-01-01 → 2024-06-30¥178m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-06-30−¥47m
—segment totalrevenue2024-01-01 → 2024-06-30¥36.3bn
—segment totalrevenue external2024-01-01 → 2024-06-30¥36.1bn
—segment totalrevenue intersegment2024-01-01 → 2024-06-30¥178m
—segment totalsegment profit2024-01-01 → 2024-06-30¥24.7bn
Reconciling Itemsreconcilingrevenue2023-01-01 → 2023-06-30−¥30m
Reconciling Itemsreconcilingrevenue intersegment2023-01-01 → 2023-06-30−¥30m
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥1.5bn
jpcrp040300-q2r_E27486-000Drug Discovery And Development Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.2bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥8.0bn
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentrevenue intersegment2023-01-01 → 2023-06-30¥30m
jpcrp040300-q2r_E27486-000Radiopharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥228m
—segment totalrevenue2023-01-01 → 2023-06-30¥9.5bn
—segment totalrevenue external2023-01-01 → 2023-06-30¥9.4bn
—segment totalrevenue intersegment2023-01-01 → 2023-06-30¥30m
—segment totalsegment profit2023-01-01 → 2023-06-30−¥941m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 586
ItemContextValueUnit
Inventories ca IFRSPrior1YearInstant2404156000JPY
Inventories ca IFRSCurrentQuarterInstant2789939000JPY
Income taxes receivable ca IFRSPrior1YearInstant－JPY
Income taxes receivable ca IFRSCurrentQuarterInstant14565000JPY
Other current assets ca IFRSPrior1YearInstant335959000JPY
Other current assets ca IFRSCurrentQuarterInstant727377000JPY
Current assets IFRSPrior1YearInstant27225082000JPY
Current assets IFRSCurrentQuarterInstant61781570000JPY
Property plant and equipment IFRSPrior1YearInstant17358317000JPY
Property plant and equipment IFRSCurrentQuarterInstant17286634000JPY
Goodwill IFRSPrior1YearInstant8370677000JPY
Goodwill IFRSCurrentQuarterInstant8370677000JPY
Intangible assets IFRSPrior1YearInstant2211452000JPY
Intangible assets IFRSCurrentQuarterInstant2141261000JPY
Investments accounted for using equity method IFRSPrior1YearInstant81067000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant－JPY
Other financial assets nca IFRSPrior1YearInstant11801205000JPY
Other financial assets nca IFRSCurrentQuarterInstant1514067000JPY
Deferred tax assets IFRSPrior1YearInstant2337218000JPY
Deferred tax assets IFRSCurrentQuarterInstant4704933000JPY
Retirement benefit asset nca IFRSPrior1YearInstant32146000JPY
Retirement benefit asset nca IFRSCurrentQuarterInstant34357000JPY
Other non current assets nca IFRSPrior1YearInstant46845000JPY
Other non current assets nca IFRSCurrentQuarterInstant47739000JPY
Non current assets IFRSPrior1YearInstant42238930000JPY
Non current assets IFRSCurrentQuarterInstant34099671000JPY
Assets IFRSPrior1YearInstant69464013000JPY
Assets IFRSCurrentQuarterInstant95881241000JPY
Trade and other payables cl IFRSPrior1YearInstant3203559000JPY
Trade and other payables cl IFRSCurrentQuarterInstant3486439000JPY
Borrowings cl IFRSPrior1YearInstant2586259000JPY
Borrowings cl IFRSCurrentQuarterInstant2589645000JPY
Other financial liabilities cl IFRSPrior1YearInstant255987000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant1025603000JPY
Income taxes payable cl IFRSPrior1YearInstant1003852000JPY
Income taxes payable cl IFRSCurrentQuarterInstant9798501000JPY
Provisions cl IFRSPrior1YearInstant31583000JPY
Provisions cl IFRSCurrentQuarterInstant16268000JPY
Contract liabilities cl IFRSPrior1YearInstant823011000JPY
Contract liabilities cl IFRSCurrentQuarterInstant674858000JPY
Other current liabilities cl IFRSPrior1YearInstant712834000JPY
Other current liabilities cl IFRSCurrentQuarterInstant658563000JPY
Total current liabilities IFRSPrior1YearInstant8617088000JPY
Total current liabilities IFRSCurrentQuarterInstant18249879000JPY
Borrowings ncl IFRSPrior1YearInstant19634447000JPY
Borrowings ncl IFRSCurrentQuarterInstant18338602000JPY
Other financial liabilities ncl IFRSPrior1YearInstant323160000JPY
Other financial liabilities ncl IFRSCurrentQuarterInstant367921000JPY
Deferred tax liabilities IFRSPrior1YearInstant385837000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-06-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2024-01-01/2024-06-30pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-06-30pass